Posts by year
2020
Can we still rely on Omega-3 & Co. for cancer prevention and management?
According to an extensive systematic review recently published in the British Journal of Cancer, there is no evidence for a protective role of polyunsaturated fat (PUFAs) against the risk of…
Right drug, wrong patient: here’s how we improve our targeting
When it comes to precision and personalised medicine (PPM), clinical practice in oncology takes pride in developing and administering treatments that selectively target components of tumour cells. But, PPM is…
COVID-19 and cancer, still more questions than answers
COVID-19 outbreak poses a severe threat to the health of millions of people worldwide, including cancer patients. What do we know about SARS-CoV-2 infection in this specific population? The analysis…
Dino Amadori passes away at the age of 83
Soul and courage: these are the two words italian oncologist Dino Amadori chose in the autobiography he published less than two years ago to describe what guided him alla along…
In memory of Aron Goldhirsch, challenging oncologist with a vision
Prof. Aron Goldhirsch, an outstanding representative of italian Medical Oncology, awarded and recognized internationally, passed away on February 26. Since 2019, he was Medical Consultant at the Breast Cancer Center…
How to make precision drugs that work better
Six lessons from the development of the first targeted anti-cancer therapy Tamoxifen famously started life as a failed contraceptive, developed by ICI (now Astra Zeneca), but with the fatal flaw…
More evidence-based info on off-patent oncology drugs
The American Association for Cancer Research (AACR) has offered help to the U.S. Food and Drug Administration (FDA) on its ambitious Project Renewal, that aims to evaluate accumulated scientific evidence…
A step forward in prostate cancer screening optimisation
A single prostate-specific antigen (PSA) measurement in midlife may help to personalise prostate cancer screening, resulting in a reduced risk of overdiagnosis and overtreatment of indolent cancers. The authors of…
Chiara Gasparotto – winning the case for better access to radiotherapy
A quarter of cancer patients who could benefit from radiotherapy do not receive it. As head of policy and partnerships, Chiara Gasparotto is positioning the European Society for Radiotherapy to…
AI will help Cinderella to see herself in the mirror
Many women who undergo breast reconstruction after mastectomy end up disappointed. It is estimated that as many as 30% of women have to live with aesthetic results they are not…